Mallinckrodt Pharmaceuticals Tech Stack

Specialty pharmaceuticals and generics manufacturer serving niche therapeutic areas

Pharmaceutical Manufacturing Dublin, Ireland 1,001–5,000 employees Founded 1867 Public Company

Mallinckrodt is a 150+ year-old pharmaceutical manufacturer operating as a public company post-2025 restructuring that split the business into two focused entities: Keenova Therapeutics (branded) and Par Health (generics and sterile injectables). The tech stack reflects a regulated manufacturing operation — lab instrumentation (HPLC, FT-IR, SDS-PAGE) paired with enterprise compliance and CRM tools (Veeva, Salesforce, SAP, Workday) — with minimal recent tech velocity and hiring concentrated in sales (20 roles) and finance (5), signaling a post-merger integration phase focused on portfolio alignment and cash management rather than product innovation.

Tech Stack 15 technologies

Core StackSAP Oracle Workday ADP HPLC FT-IR SDS-PAGE Salesforce Marketing Cloud Veeva CRM Adobe CRM Microsoft Office Adobe Acrobat Workiva Veeva

What Mallinckrodt Pharmaceuticals Is Building

◆Challenges

Nephrology sales growth
Growth in ophthalmology
Improving patient access to treatment
Low adoption of omnichannel tools
Expanding into nephrology
Reducing authorization processing time
Maximizing patient access
Monitoring investor sentiment
Expanding into ophthalmology
Capital structure optimization

▲Active Projects

Growth and adoption in key nephrology practices
Quarterly earnings announcements
Strategy alignment across portfolio
Crisis communication preparedness
Global cash forecasting
Capital structure optimization
Foreign exchange hedging
Nephrology growth initiative
Post market surveillance
Contracting and tendering processes

Hiring Activity

Minimal40 roles · 1 in 30d

Department

Sales

Finance

Marketing

Ops

Support

Legal

Logistics

Manufacturing

Seniority

Mid

Senior

Manager

Director

Lead

Junior

Notable leadership hires: Site Director

Company intelligence

Find more companies like Mallinckrodt Pharmaceuticals by tech stack, pain points and active projects

Get started free

About Mallinckrodt Pharmaceuticals

Mallinckrodt manufactures specialty pharmaceuticals, active pharmaceutical ingredients, and specialty generics across therapeutic areas including pain management, autoimmune and rare diseases, neonatal respiratory care, and hemostasis products. Following the 2025 combination with Endo and subsequent split into Keenova and Par Health, the company operates as two independent, focused businesses. Headquarters remain in Dublin, Ireland, with manufacturing and commercial operations spanning Japan, the United States, Australia, and Ireland. Current strategic priorities include nephrology and ophthalmology market expansion, patient access improvement, and post-market surveillance compliance.

HeadquartersDublin, Ireland

Company Size1,001–5,000 employees

Founded1867

Hiring MarketsJapan, United States, Australia, Ireland

Frequently Asked Questions

What is Mallinckrodt's current business structure?

In 2025, Mallinckrodt combined with Endo and restructured into two standalone companies: Keenova Therapeutics (branded therapeutics) and Par Health (generics and sterile injectables). Both operate independently.

What tech does Mallinckrodt use for manufacturing and compliance?

Lab instrumentation includes HPLC, FT-IR, and SDS-PAGE. Enterprise systems span Veeva CRM, Salesforce Marketing Cloud, SAP, Oracle, Workday, and ADP for manufacturing, compliance, and financial operations.